Bayer Faces Investor Pressure to Accelerate Turnaround Amid Record Lows
Bayer is under growing pressure from investors to expedite its turnaround strategy as CEO Bill Anderson grapples with slumping earnings and a 20-year low in the company's share price following a stark profit warning earlier this week. Some shareholders have called for a stronger focus on efficiency and drug development...